CION Cancer Clinics
Brentuximab vedotin in Hodgkin lymphoma treatment | CION Cancer Clinics
Brentuximab vedotin is a targeted drug that locks onto the CD30 marker on Hodgkin lymphoma cells and delivers chemotherapy inside them. It is used with AVD for some advanced disease, before or after a stem cell transplant, and at relapse. Its main side effect is numbness and tingling in the hands and feet. This page explains when it is used, what to expect and what to report. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
On this page
- What is brentuximab vedotin, and how does it treat Hodgkin lymphoma?
- At which points in treatment is brentuximab used?
- What happens before and on each treatment day?
- What side effects should you watch for?
- What do the words on the treatment plan mean?
- What do families often misunderstand about targeted drugs?
- Common questions about brentuximab for Hodgkin lymphoma
The short answer
What is brentuximab vedotin, and how does it treat Hodgkin lymphoma?
Brentuximab vedotin is a targeted drug that carries chemotherapy straight to Hodgkin lymphoma cells. It is used in some first treatments for advanced disease, and more often when the lymphoma has come back or not responded to standard chemotherapy.
How it finds the lymphoma
The large abnormal cells of classical Hodgkin lymphoma, called Reed-Sternberg cells, carry a marker on their surface called CD30. Brentuximab is an antibody, a protein made to latch onto CD30. Attached to the antibody is a strong cell-killing drug. Once the antibody locks on, the cell takes the drug inside, and the drug stops it dividing.
Why that matters
Because the drug is delivered mostly to cells carrying CD30, it can work when ordinary chemotherapy has not. It is not free of side effects, though. Some of the drug reaches healthy nerves, which is why numbness and tingling are its most familiar problem.
Who it does not usually suit
It is not used together with bleomycin, because the two together caused serious lung damage. People who already have significant nerve damage, for example from diabetes, may not tolerate it well. It is also not a standard option for the nodular lymphocyte-predominant type, where the cells often lack CD30.
This page explains the medicine in general. Whether it fits your treatment is decided by your haematologist.When it is used
At which points in treatment is brentuximab used?
Its place depends on the stage, what treatment has already been given, and whether a stem cell transplant is planned.
First treatment for advanced disease
Given with AVD chemotherapy, in place of bleomycin. This is written as A+AVD, and is one standard option for advanced-stage disease.
Often considered for
- People at higher risk of lung damage
- Stage IV disease in younger adults
- People unable to have bleomycin
Relapse, before a transplant
Used alone or with chemotherapy to shrink the lymphoma before an autologous stem cell transplant, where your own cells are collected and returned.
A good response before the transplant is one of the things transplant teams look for.After a transplant
For people at high risk of relapse, a course after the transplant can lower the chance of the lymphoma returning.
Transplants are arranged with qualified transplant centres.When a transplant is not possible
Older adults or people with other health problems may receive it as a main treatment for relapsed disease, to control the lymphoma for as long as possible.
Nerve checks matter even more at older ages, when balance problems raise the risk of falls.Not sure whether this applies to you?
Ask an oncologistOn the day
What happens before and on each treatment day?
Before the first cycle
A PET-CT, blood tests including sugar and liver function, and a check of feeling in your hands and feet. Mention diabetes, thyroid problems and any existing numbness now.
Checks each visit
Blood counts and liver and kidney tests are reviewed. You will be asked about numbness, tingling, cough and infections before the drip is prepared.
The drip
Brentuximab is given into a vein as a short drip in day-care. With AVD, the chemotherapy drugs are given on the same visit.
Watching for reactions
Nurses watch for chills, rash or breathlessness during and just after the drip. Tell them straight away if you feel odd.
Going home
Most people go home the same day with a schedule. With A+AVD, cycles usually repeat every two weeks. Given alone, the drip is usually every three weeks.
Being straight with you
What side effects should you watch for?
The most common problem is numbness, tingling or burning in the fingers and toes. It builds up over the course, and in some people it makes buttons, writing or walking harder.
Nerve symptoms
Report nerve symptoms early, even if they seem mild. Your team may adjust the treatment, delay a cycle or stop the drug, and acting early means they are more likely to improve. For many people the numbness eases over months after treatment ends, though it does not always go completely.
Low white cells and infection
When brentuximab is given with AVD, the infection-fighting white cells can drop sharply. Growth factor injections are often given to prevent this. A fever or shivering during treatment needs same-day hospital care.
Other effects
Tiredness, feeling sick, loose motions, hair thinning and rashes are also common. Rarely, it can cause inflammation of the pancreas, with severe pain in the upper belly, or raise blood sugar.
Reactions to the drip
A few people get chills, a rash, itching or breathlessness while the drip runs. Nurses can slow or pause it and give medicines to settle the reaction. If you had one before, you may be given preventive medicines before later cycles.
Never skip, delay or stop a cycle on your own. Changes are made by the treating team.Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
A very rare brain infection has been linked with brentuximab. Go to the nearest emergency department or call 108 if there is new confusion, trouble speaking, weakness on one side, loss of balance or a sudden change in vision. Go the same day for a fever or shivering, or severe pain in the upper belly. Say the person is on brentuximab.
On your plan
What do the words on the treatment plan mean?
- CD30
- The marker on Hodgkin cells that brentuximab latches onto. Your biopsy report usually says CD30 positive.
- Antibody-drug conjugate
- An antibody joined to a cell-killing drug, so the drug is carried to the target cells.
- A+AVD
- Brentuximab given with doxorubicin, vinblastine and dacarbazine, without bleomycin.
- Consolidation
- Treatment given after a transplant or main treatment to lower the chance of relapse.
- Refractory
- Lymphoma that did not respond well to the treatment given.
Commonly believed
What do families often misunderstand about targeted drugs?
Brentuximab is more focused than chemotherapy, but it still causes nerve damage, low counts and tiredness in many people. Plan for side effects and report them.
Newer does not mean right for everyone. For many people, standard ABVD or AVD works well with fewer nerve problems. The choice depends on stage, age and health.
Tingling is common, but it must be reported at every visit. Adjusting treatment early helps stop it getting worse and lasting.
It is one of several options after relapse, alongside checkpoint inhibitor drugs, other chemotherapy and transplant. Ask what the next steps would be.
Questions we are asked
Common questions about brentuximab for Hodgkin lymphoma
Is brentuximab a chemotherapy?
It is a targeted treatment that carries a chemotherapy-type drug. The antibody part aims it at cells with the CD30 marker, and the attached drug does the killing. So it behaves partly like a targeted drug and partly like chemotherapy, including some side effects such as low counts and hair thinning.
How long is a course of brentuximab?
It depends on why it is given. As part of first treatment, it runs alongside the chemotherapy course. After a transplant or at relapse, it can continue for longer. Your haematologist will explain the planned length and how often scans will check the response.
Will the numbness in my feet go away?
For many people it improves over months after the drug is stopped or reduced, but in some it lasts. Reporting it early gives a better chance of improvement. Protect numb feet with well-fitting footwear, check them daily for cuts, and take care on stairs.
Is brentuximab expensive?
Yes, it is a costly medicine, and the total depends on how many cycles are planned. Aarogyasri, CGHS, ECHS, EHS, PM-JAY and cashless insurance may cover it when it is part of an approved plan. Scheme rules change, so check your current entitlement before treatment starts.
Can it be given to children?
Yes, in some paediatric treatment plans for higher-risk Hodgkin lymphoma, brentuximab is combined with chemotherapy. The plans are different from adult ones. Ask your child's haematology team how it fits their protocol and what nerve checks they will do.
Can I take my diabetes and blood pressure medicines?
Usually yes, but give the team a full list, including ayurvedic and herbal products. Brentuximab can raise blood sugar, so diabetes control may need closer checks. Do not change or stop any regular medicine yourself.
Why was bleomycin removed from my plan?
Because brentuximab and bleomycin together can seriously damage the lungs. When brentuximab is added to first treatment, bleomycin is left out, and the regimen becomes A+AVD. This is a planned design, not a shortcut.
How will we know if it is working?
By PET-CT scans at planned points, and by how symptoms such as swollen glands, fevers or night sweats change. Blood tests help too. Your team will explain when the scans are due and what the results mean for the next step.
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Macmillan Cancer Support — Brentuximab
- National Cancer Institute — Brentuximab Vedotin
- National Cancer Institute — Adult Hodgkin Lymphoma Treatment (PDQ) - Patient Version
- American Cancer Society — Treating Hodgkin lymphoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Not sure what to do next?
Tell us what has been found so far and we will help you reach the right specialist. One helpline serves every CION centre.